Multiple Myeloma Treatment Algorithm
Initial Risk Stratification
All newly diagnosed symptomatic multiple myeloma patients require immediate risk stratification using International Staging System (ISS) and cytogenetic testing to classify as standard-risk versus high-risk disease before initiating therapy 1, 2. High-risk cytogenetics include del(17p), t(4;14), t(14;16), t(14;20), TP53 mutation, or gain(1q) 3.
Transplant-Eligible Patients (Age <70 years, No Major Comorbidities)
Induction Therapy (3-4 cycles pre-transplant)
Quadruplet therapy with daratumumab or isatuximab combined with bortezomib, lenalidomide, and dexamethasone (Dara-VRd or Isa-VRd) should be offered as first-line treatment 4. This represents the current standard of care based on the most recent ASCO guidelines.
Alternative preferred regimens if quadruplet unavailable:
- Bortezomib/lenalidomide/dexamethasone (VRd) - Category 1 preferred option with median PFS of 41 months and demonstrated superiority over lenalidomide/dexamethasone 1
- Daratumumab/bortezomib/thalidomide/dexamethasone (Dara-VTD) 5
- Bortezomib/cyclophosphamide/dexamethasone (CyBorD) - particularly for acute renal insufficiency, with 88% ORR and option to switch to VRd after renal recovery 1
Critical consideration: Avoid prolonged exposure to alkylating agents (melphalan, nitrosoureas) to preserve stem cell reserve for harvest 6.
Autologous Stem Cell Transplantation
High-dose melphalan 200 mg/m² followed by autologous stem cell transplantation remains standard of care 7, 2.
For high-risk cytogenetics or failure to achieve ≥CR after first transplant, consider tandem (double) transplantation 7.
Maintenance Therapy
Standard-risk patients: Lenalidomide maintenance (Category 1) should be continued until disease progression 1, 2, 5. This increases PFS and possibly OS 2.
High-risk patients: Proteasome inhibitor-IMiD combinations (such as lenalidomide with bortezomib or carfilzomib) with or without daratumumab should be used 4, 3.
Important caveat: Discuss increased risk of secondary malignancies with lenalidomide maintenance post-transplant, though benefits typically outweigh risks 6.
Transplant-Ineligible Patients (Age ≥70 years, Significant Comorbidities, or Patient Preference)
Primary Therapy (Continued Until Progression)
Quadruplet therapy with daratumumab or isatuximab combined with bortezomib, lenalidomide, and dexamethasone should be offered to suitable patients 4. The CEPHEUS trial demonstrated 60.9% MRD-negativity with D-VRd versus 39.4% with VRd, with 43% lower risk of progression or death 8.
Standard-risk disease - preferred triplet regimens:
- Daratumumab/lenalidomide/dexamethasone (Dara-Rd) continuously until progression - Category 1 preferred 9, 5. The MAIA trial showed 70.6% PFS at 30 months versus 55.6% with Rd alone 5
- Lenalidomide/low-dose dexamethasone continuously - Category 1 option with 91% OS at 2 years in non-transplant patients and demonstrated superiority over melphalan-based regimens 1
High-risk disease or renal insufficiency - bortezomib-containing regimens:
- Bortezomib/lenalidomide/dexamethasone (VRd) - median PFS 41 months versus 29 months with Rd alone 1, 10
- Daratumumab/bortezomib/melphalan/prednisone (Dara-VMP) - Category 1 option with 72% PFS at 18 months versus 50% with VMP 1, 5
- Cyclophosphamide/bortezomib/dexamethasone (CyBorD) - especially for acute renal failure 1
For frail or elderly patients unable to tolerate triplets, doublet regimens may be initiated with plan to add third agent once performance status improves 6, 9.
Dosing Modifications for Tolerability
Use subcutaneous bortezomib (preferred over IV) and weekly dosing (instead of twice-weekly) to reduce peripheral neuropathy while maintaining efficacy 6, 11.
VRd-lite regimen: Subcutaneous bortezomib 1.3 mg/m² on days 1,8,15,22 with dexamethasone 20 mg on day of and after bortezomib, omitting lenalidomide on bortezomib days - achieves 83% ORR with reduced toxicity 1.
Essential Supportive Care Measures
Thromboprophylaxis: Full-dose aspirin required with all immunomodulator-based therapy; therapeutic anticoagulation for high-risk patients 6, 9.
Herpes zoster prophylaxis: Mandatory for all patients receiving proteasome inhibitors 6, 9.
Bone-directed therapy: Two-year course of bisphosphonates (zoledronic acid or pamidronate) or denosumab, with extended dosing intervals if disease stable 12.
Key Clinical Pitfalls to Avoid
Do not use melphalan-containing regimens in transplant-eligible patients - this compromises stem cell reserve and limits future transplant options 6, 11.
Do not discontinue therapy in responding patients - continuous therapy until progression is superior to fixed-duration treatment, particularly with lenalidomide-based regimens 1.
Do not use high-dose dexamethasone (40 mg) in elderly patients - low-dose dexamethasone (20 mg) has superior survival outcomes, especially in patients ≥65 years 1.
Do not delay cytogenetic risk stratification - high-risk patients require more intensive bortezomib-containing regimens from the outset 1, 11, 3.